When time is of essence and every moment counts, Southern Tier Cancer Care is here…
Welcome to STCC
We realize that you are apprehensive and fearful. By providing professional assistance through education, the latest approved treatments available and most importantly, compassionate care, we are dedicated to guiding patients to hope, help, and healing.
Southern Tier Cancer Care Team is Committed to
Excellence in Providing Comprehensive, Up to date,
Compassionate and Quality care for Cancer Patients.
EMERGENCIES /AFTER HOURS
Please proceed immediately to the nearest emergency room for any medical emergencies especially fever greater than or equal to 100.4 while on chemotherapy.If you need to reach Dr Soni immediately for problems related to cancer or chemotherapy,
Please call the answering service at (716) 559 1105.
Please call your primary physician or emergency room at Olean General Hospital at (716) 375 4149 for any urgent concerns after office hours or if Dr Soni is away.
News & Updates
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward [Pediatric Oncology]
The use of radiographic response as the primary end point in phase II osteosarcoma trials may limit optimal detection of treatment response because of the calcified tumor matrix. We performed this study to determine if time to progression could be used as an end point for subsequent studies.Patients and Methods
We performed a retrospective analysis of outcome for patients with recurrent/refractory osteosarcoma enrolled in one of seven phase II trials conducted by the Children’s Oncology Group and predecessor groups from 1997 to 2007. All trials used RECIST or WHO radiographic response criteria and the primary end point of response rate. The following potential prognostic factors—age, trial, number of prior chemotherapy regimens, sex, and race/ethnicity—were evaluated for their impact on event-free survival (EFS). We used data from a phase II study (AOST0221) of patients with osteosarcoma who were given inhaled granulocyte-macrophage colony-stimulating factor with first pulmonary recurrence who had an EFS as well as biologic end point to determine the historical disease control rate for patients with fully resected disease.Results
In each included trial, the drugs tested were determined to be inactive on the basis of radiographic response rates. The EFS for 96 patients with osteosarcoma and measurable disease was 12% at 4 months (95% CI, 6% to 19%). There was no significant difference in EFS across trials according to number of prior treatment regimens or patient age, sex, and ethnicity. The 12-month EFS for the 42 evaluable patients enrolled in AOST0221 was 20% (95% CI, 10% to 34%).Conclusion
The EFS was uniformly poor for children with recurrent/refractory osteosarcoma in these single-arm phase II trials. We have now constructed baseline EFS outcomes that can be used as a comparison for future phase II trials for recurrent osteosarcoma.
Researchers have identified a mechanism in mice by which anticancer immune responses are inhibited within the lungs, a common site of metastasis for many cancers.
A fact sheet that discusses the advantages and disadvantages of several colorectal cancer screening tests.
People with personal experience with cancer help inform research grant selections
Public Health Landmark Achieved as 80% by 2018 Colorectal Cancer Screening Campaign Reaches 1,000th Pledge
Nationwide Effort Could Prevent 277,000 Colorectal Cancer Cases and 203,000 Deaths by 2030